Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis

Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis

Abstract Background and aims Limited data is available on the efficacy of direct acting anti-viral drugs on hepatitis C in drug users. The aim of this meta-analysis was to comprehensively analyze the efficacy and safety of LDV/SOF in drug users infected with the hepatitis C virus (HCV). Methods The...

Full description

Bibliographic Details
Main Authors:	Xue Yang, Yang Tang, Di Xu, Guang Zhang, Peng Xu, Houlin Tang, Lin Pang
Format:	Article
Language:	English
Published:	BMC 2021-07-01
Series:	Virology Journal
Subjects:	Hepatitis C Ledipasvir and sofosbuvir Drug users SVR12 Meta-analysis
Online Access:	https://doi.org/10.1186/s12985-021-01625-w

Similar Items

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2017-03-01)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
by: Tingting Tao, et al.
Published: (2017-02-01)

The impact of sofosbuvir/ledipasvir on chronic hepatitis C-infected paediatric patients: a Middle East single-centre experience
by: Mohammad Fadhil Ibraheem, et al.
Published: (2023-11-01)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
by: Mohammed A Babatin, et al.
Published: (2019-01-01)

Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan
by: Hung-Chih Chiu, et al.
Published: (2021-03-01)

Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
by: Oidov Baatarkhuu, et al.
Published: (2021-01-01)

Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Successful Treatment of Hepatitis C Virus by Ledipasvir/Sofosbuvir in a Cirrhotic Patient with Sickle Cell Disease and Thalassemia Minor
by: Hassan Al Moussawi, et al.
Published: (2018-10-01)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016-06-01)

The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C
by: Maria Pokorska-Śpiewak, et al.
Published: (2022-02-01)

Cardiac arrhythmia due to ledipasvir/sofosbuvir Iranian counterpart, commercially named as Ledibiox: A case report
by: Alireza Heidari Bakavoli, et al.
Published: (2020-09-01)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
by: Heidar Sharafi, et al.
Published: (2020-01-01)

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
by: Chantelli Iamblaudiot Razafindrazoto, et al.
Published: (2021-06-01)

Delayed-Type Hypersensitivity Reaction to Red Tattoo Ink Triggered by Ledipasvir/Sofosbuvir for Hepatitis C: A Case Report
by: Meghan L. McPhie, et al.
Published: (2021-07-01)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting
by: Dorota Zarębska-Michaluk, et al.
Published: (2019-07-01)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
by: Nadia Marascio, et al.
Published: (2019-05-01)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
by: Vincent Alcazer, et al.
Published: (2018-12-01)

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms
by: Essam Ezzeldin, et al.
Published: (2020-10-01)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
by: Soon Kyu Lee, et al.
Published: (2022-11-01)

Simultaneous spectrophotometric determination of recombined sofosbuvir, ledipasvir and paracetamol together as commonly repurposed drugs for COVID-19 treatment
by: Sherif Gamal, et al.
Published: (2023-08-01)

Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
by: Maria Pokorska-Śpiewak, et al.
Published: (2022-08-01)

Sofosbuvir/ledipasvir safety and efficacy for HCV patients with haemodialysis and liver cirrhosis: a small retrospective study
by: Ebtisam Boushi, et al.
Published: (2021-10-01)

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
by: Ching-Chu Lo, et al.
Published: (2022-08-01)

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
by: Maria Pokorska-Śpiewak, et al.
Published: (2021-09-01)

Rapid and validated UHPLC method for simultaneous determination of sofosbuvir, ledipasvir and paracetamol as commonly repurposed drugs for COVID-19 treatment: application in spiked human plasma
by: Sherif Gamal, et al.
Published: (2023-10-01)

Efficacy and safety of Sofosbuvir-containing regimens in patients co-infected with chronic hepatitis C virus and human immunodeficiency virus: a meta-analysis
by: Guotao Li, et al.
Published: (2018-01-01)

Simultaneous chromatographic analysis of Sofosbuvir/Ledipasvir in their combined dosage form: an application to green analytical chemistry
by: Ahmed Hemdan, et al.
Published: (2019-12-01)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
by: Melissa J. Barber, et al.
Published: (2020-09-01)

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China
by: Hui Jun Zhou, et al.
Published: (2021-12-01)

Should they wait? Two children under 3 years old infected by HCV 1b successfully treated by ledipasvir/sofosbuvir: A report of two cases
by: Mingna Li, et al.
Published: (2023-12-01)

Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
by: Seong Hee Kang, et al.
Published: (2021-01-01)

Safety and efficacy of directly acting antivirals (sofosbuvir and daclatasvir) in treatment of chronic HCV in HIV-HCV co-infected Egyptian patients
by: Inas E L-Khedr Mohamed, et al.
Published: (2021-04-01)

Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study
by: Cristina Aurora São Pedro Soeiro, et al.
Published: (2018-08-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study
by: Mekky MA, et al.
Published: (2019-01-01)

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
by: Mostafa Yakoot, et al.
Published: (2017-07-01)

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service
by: Westerhout KY, et al.
Published: (2017-02-01)

Multivariate optimization and evaluation of quaternary mixture in bulk and co-formulated dosage forms by central composite design
by: Rama Tulasi Jampana, et al.
Published: (2021-05-01)